Vaccine News and Research

Latest Vaccine News and Research

How the human brain processes incoming sensory signals amidst background noise

The brain never sits idle. Whether we are awake or asleep, watch TV or close our eyes, waves of spontaneous nerve signals wash through our brains. Researchers at the Salk Institute for Biological Studies studying visual attention have discovered a novel mechanism that explains how incoming sensory signals make themselves heard amidst the constant background rumblings so they can be reliably processed and passed on.

24 Sep 2009

Phase III efficacy trial of two AIDS vaccine candidates shows promise

The International AIDS Vaccine Initiative (IAVI) greeted with excitement today’s announcement by the U.S. Military HIV Research Program and the Thai Ministry of Public Health that, according to an initial analysis, a prime-boost combination of two AIDS vaccine candidates has shown partial efficacy in a phase III efficacy trial in Thailand. The prime-boost combination appeared to be about 31% effective at preventing infection with HIV.

24 Sep 2009

CEL-SCI Corporation engages a CRO for clinical trial of its investigational LEAPS-H1N1 treatment

CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines and therapeutics for the treatment of infectious diseases and a late-stage oncology company, announced today that it has hired a full-service Clinical Research Organization (CRO) with an office in the Washington, D.C./Baltimore area to support its conduct of the upcoming clinical trial of its investigational LEAPS-H1N1 treatment.

24 Sep 2009

It is possible to reduce the risk of HIV infection with a vaccine: AVAC

"Today marks an historic milestone in the search for an AIDS vaccine; we now have evidence that it is possible to reduce the risk of HIV infection with a vaccine," said AVAC executive director Mitchell Warren, reacting to the results of the first AIDS vaccine trial to ever show efficacy at preventing HIV. "It will take time and resources to fully analyze, understand and validate the data, but there is little doubt that this finding will energize and redirect the AIDS vaccine field as all of us begin the hard work to translate this landmark result into true public health benefit."

24 Sep 2009

Results of Phase III clinical trial of HIV vaccine released

A Phase III clinical trial involving more than 16,000 adult volunteers in Thailand has demonstrated that an investigational HIV vaccine regimen was safe and modestly effective in preventing HIV infection. According to final results released by the trial sponsor, the U.S. Army Surgeon General, the prime boost combination of ALVAC(R)( )HIV and AIDSVAX(R) B/E( )lowered the rate of HIV infection by 31.2% compared with placebo.

24 Sep 2009

Rescuing immune system cells can reduce risk of prostate cancer

Immune therapies have been explored as a way to treat cancer after it develops. But a new study from the University of Michigan Comprehensive Cancer Center suggests that genetic risk of prostate cancer can be reduced by rescuing critical immune system cells.

24 Sep 2009

Pregnant women must be vaccinated against H1N1 and seasonal flu

Pregnant women should be sure to get all their flu shots as soon as the vaccines become available this year to protect them against both the seasonal flu and the H1N1 (swine) flu, according to eight leading national maternal and infant health organizations.

24 Sep 2009

Study of new swine flu vaccines looks for local children to take part

Paediatricians at Bristol Children's Vaccine Centre are looking for 170 children to take part in a study of the two swine 'flu vaccines due to be used in the UK this winter.

23 Sep 2009

ImmunoCellular Therapeutics completes humanization of its ICT-37 and ICT-109 antibody candidates

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has completed humanization of ICT-37 and ICT-109.

23 Sep 2009

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).

23 Sep 2009

PSI to double its HIV prevention programs

PSI (Population Services International) announced two significant commitments today at the Clinton Global Initiative (CGI): a doubling of its HIV prevention programs that target at-risk men and, in partnership with Procter & Gamble's Children's Safe Drinking Water program, a commitment that will expand the availability of safe drinking water to vulnerable populations across the globe.

23 Sep 2009

EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patients

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) demonstrated a significant improvement in overall survival (OS) when added to standard 1st-line chemotherapy for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors.

23 Sep 2009

Children’s Hospital offers tips on H1N1 and seasonal flu

With the early onset of flu season coinciding with the start of school this year, parents are concerned about the flu. Experts from The Children’s Hospital in Denver, Colo., offer a pediatric perspective on all types of flu, including H1N1, also known as swine flu.

23 Sep 2009

British Prime Minister to unveil $1b effort to improve health systems in developing countries

During the U.N. General Assembly meeting in New York, British Prime Minister Gordon Brown on Wednesday is scheduled to announce that Britain is teaming up with Norway, the Netherlands and Australia to invest $1 billion to strengthen the health systems in developing countries, the Financial Times/NineMSN reports (Jack, 9/21).

23 Sep 2009

Chan calls for additional H1N1 vaccines for poor countries during WHO Asia-Pacific regional meeting

During the WHO Asia-Pacific regional meeting Monday, WHO Director-General Margaret Chan discussed the organization's efforts to ensure that poor nations have access to H1N1 vaccines, VOA News reports (Bayron, 9/21).

23 Sep 2009

Government orders additional H1N1 vaccine

Associated Press/Boston Globe reports that on Monday, "the United States ordered more swine flu vaccine, bringing its eventual total to 251 million doses, up from the long-planned 195 million doses.

23 Sep 2009

Sanofi Pasteur receives additional order H1N1 vaccine

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the company has received an additional order from the U.S. Department of Health and Human Services (HHS) to produce vaccine to help protect against the Influenza A (H1N1) 2009 virus. The new order is for the production of bulk antigen equivalent to 27.3 million doses based on 15 mcg of antigen per dose.

22 Sep 2009

Advaxis' patent approval enables the development of new vaccines with additional properties

The United States Patent and Trademark Office (USPTO) has granted and issued Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, patent 7,588,930 “Compositions and Methods for Enhancing Immunogenicity of Antigens.” This patent expands the Company’s intellectual property portfolio to cover another family of adjuvant proteins based upon the Lm protein Act-A.

22 Sep 2009

Cancer Research UK invests £16 million in new Drug Discovery Programes at Manchester and Glasgow

CANCER RESEARCH UK is set to extend its drug discovery effort by investing up to £16 million in two new Drug Discovery Programmes at the Paterson Institute for Cancer Research in Manchester and the Beatson Institute for Cancer Research in Glasgow.

22 Sep 2009

Millions of H1N1 healthcare consent forms - how to manage them?

As health officials prepare to roll out millions of H1N1 swine flu vaccines this fall, many are contemplating whether to get the shot or risk coming down with the illness. Yet for officials at the state and local level, the question isn’t whether to get the shot, but what to do with the millions of pages of healthcare forms that will begin piling up once the shot becomes available later this year.

22 Sep 2009

Vaccine News and Research

Latest Vaccine News and Research

How the human brain processes incoming sensory signals amidst background noise

Phase III efficacy trial of two AIDS vaccine candidates shows promise

CEL-SCI Corporation engages a CRO for clinical trial of its investigational LEAPS-H1N1 treatment

It is possible to reduce the risk of HIV infection with a vaccine: AVAC

Results of Phase III clinical trial of HIV vaccine released

Rescuing immune system cells can reduce risk of prostate cancer

Pregnant women must be vaccinated against H1N1 and seasonal flu

Study of new swine flu vaccines looks for local children to take part

ImmunoCellular Therapeutics completes humanization of its ICT-37 and ICT-109 antibody candidates

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

PSI to double its HIV prevention programs

EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patients

Children’s Hospital offers tips on H1N1 and seasonal flu

British Prime Minister to unveil $1b effort to improve health systems in developing countries

Chan calls for additional H1N1 vaccines for poor countries during WHO Asia-Pacific regional meeting

Government orders additional H1N1 vaccine

Sanofi Pasteur receives additional order H1N1 vaccine

Advaxis' patent approval enables the development of new vaccines with additional properties

Cancer Research UK invests £16 million in new Drug Discovery Programes at Manchester and Glasgow

Millions of H1N1 healthcare consent forms - how to manage them?

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in